GYRE THERAPEUTICS, INC. quarterly report, Q3 FY2023

GYRE THERAPEUTICS, INC. — Filing identity and period

Important identification note: The supplied filing is Catalyst Biosciences, Inc.’s Form 10-Q for the quarter ended September 30, 2023, not a filing bearing the name Gyre Therapeutics, Inc. The summary below reflects the filing text provided.

Catalyst had ceased its earlier research programs and acquired rights outside China to F351, a clinical-stage candidate for liver fibrosis, in December 2022. It was also pursuing a business combination to acquire an indirect controlling interest in China-based Beijing Continent Pharmaceutical (BC). The statements are unaudited.

Financial results and liquidity

Metric	Three months ended September 30, 2023	Nine months ended September 30, 2023
Revenue	None	None
Net loss	$1.6 million	$3.8 million
Research and development expense	$0.4 million	$1.3 million
General and administrative expense	$2.4 million	$8.6 million
GNI cost-sharing reimbursement recognized	$1.2 million	$1.2 million
Operating cash used	Not presented for the quarter	$11.9 million

At September 30, 2023, cash and cash equivalents were $2.2 million, total current assets were $5.1 million, total assets were $10.0 million, current liabilities were $1.8 million, and total liabilities were $6.4 million. Stockholders’ equity was $3.5 million; accumulated deficit was $414.7 million. The filing reports no borrowings or debt balance.

Cash declined $19.4 million over the first nine months, from $21.7 million to $2.2 million. Investing activities provided $5.2 million, including $5.0 million received from Vertex and $1.0 million upfront from the GCBP asset sale, partly offset by $0.8 million transaction costs. Financing activities used $12.7 million, primarily for dividends and CVR distributions. No profit margin is meaningful because the company reported no revenue in 2023.

Changes versus the prior comparable period

• Third-quarter net loss narrowed to $1.6 million from $4.9 million in 2022, mainly as operating expenses fell 69% to $1.6 million, including the $1.2 million GNI reimbursement.
• Nine-month results shifted from $32.2 million net income in 2022 to a $3.8 million net loss in 2023. The 2022 profit included a $57.2 million net gain on asset disposals, principally the Vertex portfolio sale; 2023 included a $4.7 million gain on the GCBP sale.
• Nine-month R&D expense fell 89% and G&A fell 35% year over year, reflecting discontinued legacy programs and lower operating costs. Collaboration revenue of $0.8 million in 2022 was absent in 2023.
• Operating cash use improved to $11.9 million from $31.6 million in the prior-year period, but cash at period-end was substantially lower.

Transactions, outlook and risks

• Stockholders approved the proposed BC business combination and conversion of Catalyst’s Series X preferred stock in August 2023. The transaction had not closed by September 30; BC received China Securities Regulatory Commission approval on October 20, 2023. The parties expected completion by the agreement’s outside date, but closing remained subject to conditions.
• At closing, Catalyst could issue up to 1,110,776,224 common shares for the BC interest. The filing also describes 12,340 preferred shares convertible into 123.4 million common shares, subject to conversion limits. The scale of potential dilution is material.
• GNI agreed to share certain operating costs pending closing. Reimbursement timing and amount are not fully within Catalyst’s control; the recognized $1.2 million receivable was for approved costs through June 30. Third-quarter costs remained subject to GNI approval.
• Management stated that the pending transaction’s uncertainties create substantial doubt about the company’s ability to continue as a going concern for at least 12 months after issuance of the statements. Catalyst said future funding could depend on asset sales, equity or debt financing, collaborations, alliances, or licensing; no assurance was given that funding would be available on acceptable terms.
• The GCBP sale includes a $5.0 million holdback expected in the first quarter of 2025, subject to indemnification conditions. Its fair value was recorded as a $4.7 million receivable and corresponding CVR liability; net proceeds are intended for CVR holders, not general corporate liquidity.
• Nasdaq had cited both minimum bid-price and stockholders’ equity deficiencies. The filing says delisting could harm trading liquidity, financing access, and the proposed transaction; there was no assurance the combined company would meet Nasdaq’s initial listing requirements.
• Other disclosed exposures include a possible $2.0 million termination fee under specified transaction circumstances, potential expense reimbursements up to $2.0 million, and dependence on collection of receivables and GNI cost sharing. No material legal proceedings were reported.

Most important facts for investors to verify

1. Whether the BC business combination closed, its final terms, and the number and class of shares issued.
2. Current cash runway, operating needs, GNI reimbursements received or approved, and any subsequent financing.
3. Nasdaq listing status and compliance with applicable listing requirements.
4. Conversion and ownership-blocker terms for the Series X preferred stock and the resulting fully diluted share count.
5. Timing and conditions for the GCBP holdback, related CVR distributions, and any other contingent claims or obligations.